
AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Research analysts at HC Wainwright issued their Q2 2027 EPS estimates for shares of AnaptysBio in a report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of $0.38 per share for the quarter. HC Wainwright has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($1.30) per share.
ANAB has been the subject of a number of other reports. Scotiabank cut AnaptysBio to a “hold” rating and set a $70.00 target price for the company. in a report on Tuesday, August 25th. Leerink Partners cut their price target on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 23rd. TD Cowen reduced their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a research report on Wednesday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a research note on Tuesday, September 22nd. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $75.67.
AnaptysBio Trading Up 3.2%
NASDAQ:ANAB opened at $47.06 on Tuesday. AnaptysBio has a 52 week low of $22.07 and a 52 week high of $72.36. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.40 and a current ratio of 8.40. The stock’s fifty day moving average is $49.17 and its two-hundred day moving average is $56.27.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biotechnology company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($1.84) by $1.95. AnaptysBio had a net margin of 96.30% and a negative return on equity of 17.54%. The company had revenue of $30.27 million during the quarter, compared to the consensus estimate of $25.56 million.
Insider Transactions at AnaptysBio
In related news, Director Ecor1 Capital, Llc purchased 138,093 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were purchased at an average price of $46.54 per share, with a total value of $6,426,848.22. Following the completion of the acquisition, the director directly owned 8,254,674 shares in the company, valued at $384,172,527.96. This represents a 1.70% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Hollings Renton sold 5,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total value of $249,350.00. Following the completion of the transaction, the director owned 10,995 shares in the company, valued at $548,320.65. This trade represents a 31.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders purchased 374,580 shares of company stock valued at $17,224,845. Insiders own 31.50% of the company’s stock.
Institutional Investors Weigh In On AnaptysBio
Several institutional investors have recently made changes to their positions in ANAB. Irenic Capital Management LP bought a new stake in shares of AnaptysBio in the 2nd quarter worth approximately $4,755,000. Bank of New York Mellon Corp bought a new position in AnaptysBio during the 2nd quarter worth $3,807,000. Squarepoint Ops LLC grew its stake in AnaptysBio by 21.2% during the 2nd quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock worth $21,900,000 after buying an additional 56,743 shares during the last quarter. Hsbc Holdings PLC bought a new position in AnaptysBio during the 1st quarter worth $7,137,000. Finally, Bank of America Corp DE acquired a new stake in AnaptysBio in the second quarter worth $28,202,000.
Key Headlines Impacting AnaptysBio
Here are a few of the latest headlines about ANAB:
- Positive Sentiment: Director Ecor1 Capital bought a combined 374,580 shares over November 16–18, investing approximately $17.2 million at prices of $45.66–$46.54 per share. The repeated purchases and increased stake may signal confidence in AnaptysBio. SEC insider transaction filing
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $95 price target, and estimated Q2 2027 EPS of $0.38. The target offers a bullish counterpoint to the company’s current-year consensus estimate of a loss per share. Analyst coverage
- Neutral Sentiment: AnaptysBio presented at the UBS Global Biopharma Conference, with transcripts published. The available article details do not specify new guidance or developments that would clearly affect the stock. Conference transcript
About AnaptysBio
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Recommended Stories
- Five stocks we like better than AnaptysBio
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
